Form 4: Encompass Health CEO's Stock Transactions Reported
Insider Transaction Report
Encompass Health Corp's President & CEO, Mark J. Tarr, reported the acquisition of stock options and the disposition of shares for tax obligations.
Summary
- Mark J. Tarr, President & CEO and Director of Encompass Health Corp, reported transactions involving company stock.
- On February 28, 2026, 2,187 shares of Encompass Health Common Stock were disposed of at a price of $107.88 per share.
- These shares were withheld or surrendered to cover tax withholding obligations related to the vesting of restricted stock.
- Following this transaction, Tarr beneficially owns 440,962 shares of common stock directly.
- On March 2, 2026, Tarr was granted 35,461 non-qualified stock options with an exercise price of $108.06 per share.
- These options become exercisable in equal annual installments over a three-year period starting March 2, 2027, and expire on March 2, 2036.
- Following this grant, Tarr beneficially owns 35,461 derivative securities (options) directly.
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a moderately positive filing, primarily due to the grant of new stock options to the CEO, which aligns executive incentives with future company performance, despite a routine tax-related share disposition.
Positives
- The grant of 35,461 non-qualified stock options to President & CEO Mark J. Tarr aligns management's incentives with long-term shareholder value.
- The options have an exercise price of $108.06, indicating a future growth expectation for the stock.
Negatives
- The disposition of 2,187 shares of common stock, valued at $107.88 per share, reduced direct beneficial ownership for tax withholding purposes, though this is a non-discretionary sale.
Future Outlook
This filing does not contain forward-looking statements or guidance regarding the company's financial performance or strategic outlook, focusing solely on insider transactions.
Industry Context
StockSavvy.ai notes that these insider transactions are routine compensation-related events for a public company executive and do not inherently reflect broader industry trends or competitive positioning within the healthcare sector.
Stakeholder Impact
- Shareholders: The grant of stock options to the CEO can be seen as a positive for shareholders, as it ties executive compensation to the company's stock performance, potentially aligning interests for long-term value creation. The tax-related disposition is a minor, non-discretionary event.
Next Steps
- The granted stock options will become exercisable in equal annual installments over a three-year period commencing March 2, 2027.
Key Dates
| Date | Description |
|---|---|
| 02/28/2026 | Date of disposition of common stock for tax withholding obligations. |
| 03/02/2026 | Date of grant for non-qualified stock options. |
| 03/02/2027 | Date when the first installment of the granted stock options becomes exercisable. |
| 03/02/2036 | Expiration date of the granted non-qualified stock options. |
Keywords
EHC, Encompass Health, Form 4, Insider Transaction, Stock Options, CEO, Mark Tarr, Equity Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.